Machine signal
Active cluster sell — 6 distinct insiders, $338.8M, window ends Sep 4, 2026.
Figures computed from official regulatory filings — .
Analysttarget 138.64 USD (+26%) · consensus 4.65/5 · 21 buy · 2 hold · 0 sell
Ownershipinsiders 2.12% · institutions 119.28% · short 16.3% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Kymera Therapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
45 buys499 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Mainolfi Nello | Exercise | $62.4K | SEC |
| Mainolfi Nello | Sell | $619K | SEC |
| Mainolfi Nello | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Mainolfi Nello | Sell | $552.2K | SEC |
| Mainolfi Nello | Sell | $949.7K | SEC |
| Mainolfi Nello | Sell | $392.8K | SEC |
| Mainolfi Nello | Sell | $869.8K | SEC |
| Mainolfi Nello | Sell | $30.4K | SEC |
| Adams Brian | Sell | $353.4K | Unusual size | SEC |
| Adams Brian | Sell | $251.2K | Unusual size | SEC |
| Adams Brian | Sell | $139.7K | Unusual size | SEC |
| Rooney Terence | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Rooney Terence | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Mainolfi Nello | Exercise | $104K | SEC |
| Mainolfi Nello | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Mainolfi Nello | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Mainolfi Nello | Sell | $6M | Unusual size | SEC |
| Booth Brucetrack record | Sell | $290.7K | SEC |
| Booth Brucetrack record | Sell | $81.5K | SEC |
| Jacobs Bruce N. | Sell | $719.9K | SEC |
| Booth Brucetrack record | Sell | $119.3K | SEC |
| Mainolfi Nello | Sell | $388.8K | SEC |
| Booth Brucetrack record | Sell | $587K | SEC |
| Booth Brucetrack record | Sell | $14.5K | SEC |
| Goodman Noah | Sell | $387.3K | Unusual size | SEC |